$16.90
arrow_drop_down1.74%Key Stats | |
---|---|
Open | $17.23 |
Prev. Close | $17.20 |
EPS | 1.33 |
Next Earnings Date | Jan 16, 2025 |
LOW | HIGH | |
---|---|---|
Day Range | 16.89 | 17.56 |
52 Week Range | 15.54 | 28.48 |
Ratios | |
---|---|
Revenue | - |
EPS | 1.33 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Darolutamidi yhdessä ADT-hoidon kanssa pienensi merkitsevästi (46 prosentilla) syövän etenemisen tai kuoleman riskiä verrattuna lumelääkkeen ja ADT:n yhdistelmään levinnyttä hormonisensitiivistä eturauhassyöpää sairastavilla potilailla
Inside information: Phase III ARANOTE trial of darolutamide - GlobeNewswire
Minerals Technologies (MTX) Surpasses Q1 Earnings Estimates
PPG Industries (PPG) Q1 Earnings Match Estimates
Orion (OEC) Breaks Ground on Texas Battery Materials Plant
New Strong Sell Stocks for April 5th